Viking Therapeutics (VKTX) Change in Acquisitions & Divestments (2016 - 2026)
Viking Therapeutics (VKTX) has disclosed Change in Acquisitions & Divestments for 12 consecutive years, with $126.6 million as the latest value for Q1 2026.
- For Q1 2026, Change in Acquisitions & Divestments fell 57.2% year-over-year to $126.6 million; the TTM value through Mar 2026 reached $590.2 million, down 17.92%, while the annual FY2025 figure was $759.4 million, 35.61% up from the prior year.
- Change in Acquisitions & Divestments hit $126.6 million in Q1 2026 for Viking Therapeutics, up from $116.1 million in the prior quarter.
- Across five years, Change in Acquisitions & Divestments topped out at $295.9 million in Q1 2025 and bottomed at $32.3 million in Q1 2022.
- Average Change in Acquisitions & Divestments over 5 years is $113.0 million, with a median of $116.1 million recorded in 2025.
- Year-over-year, Change in Acquisitions & Divestments surged 163.05% in 2024 and then tumbled 57.2% in 2026.
- Viking Therapeutics' Change in Acquisitions & Divestments stood at $51.9 million in 2022, then surged by 156.94% to $133.3 million in 2023, then grew by 7.71% to $143.5 million in 2024, then fell by 19.12% to $116.1 million in 2025, then rose by 9.06% to $126.6 million in 2026.
- According to Business Quant data, Change in Acquisitions & Divestments over the past three periods came in at $126.6 million, $116.1 million, and $181.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.